COMBINATIONS COMPRISING IMATINIB MESYLATE AND DICLOFENAC

摘要

The present invention relates to a method of treating Philadelphia-positive leukemia (Ph+ leukemia), especially chronic myeloid leukemia (CML), especially in human patients having low OCT-1 Activity ("low OA patients"), a combination comprising (a) imatinib or a pharmaceutically acceptable salt thereof and (b) diclofenac or a pharmaceutically acceptable salt thereof, the use of such combination for the manufacture of a medicament for the treatment of Ph+ leukemia and to a pharmaceutical composition comprising a quantity which is jointly therapeutically effective against a proliferative disease of a such combination.